Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Source : https://heart.bmj.com/content/early/2022/05/03/heartjnl-2021-320556
Objective To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. Methods This systematic review included randomised controlled trials that compared PCSK9 inhibitors...
Conclusions: PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular pain.
Share
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Source : https://www.sciencedirect.com/science/article/abs/pii/S1936878X22001437?via=ihub
The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition. The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab produced...
Conclusions: The combination of statin and evolocumab after a non–ST-segment elevation myocardial infarction produces favorable changes in coronary atherosclerosis consistent with stabilization and regression. This demonstrates a potential mechanism for the improved clinical outcomes observed achieving very low LDL-C levels following an...
Share
Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039577/
Language: English | French Shyann Hang, BSc, a Julieta Lazarte, PhD, a, b, c and Robert A. Hegele, MD a, b, c, ∗ We evaluated whether low-density lipoprotein cholesterol (LDL-C)...
Relevance: We evaluated whether low-density lipoprotein cholesterol (LDL-C) levels in familial hypercholesterolemia patients on triple lipid-lowering therapy would remain below intensification threshold values after withdrawal of ezetimibe.
Share
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35467312/
doi: 10.1007/s10557-021-07276-x. Online ahead of print. 1 The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing, China. 2 School of Pharmacy, Hangzhou Medical College, Hangzhou, China....
Conclusion: Compared with ezetimibe statins, the combination of evolocumab statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China.
Share
Approach to patients with elevated low-density lipoprotein cholesterol levels - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35487874/
Elevated low-density lipoprotein cholesterol (LDL-C) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and lowering LDL-C levels reduces the risk of ASCVD. In patients with elevated LDL-C levels it...
Conclusion: Specifically, we discuss evidence indicating that the sooner one initiates therapy the better and the greater the reduction in LDL-C the better. Additionally, the higher the LDL-C level and the higher the risk of ASCVD, the greater the benefits of treatment. Using these principles will help in making decisions regarding the...
Share